Journal article

Challenges of phase III trial design for novel treatments in diseases with no standard treatment: The AZA-001 myelodysplasia study model

Pierre Fenaux, John F Seymour, Valeria Santini, Lew Silverman, Steven Gore, Alan List, Guillermo Sanz, Ghulam J Mufti, Eli Estey, Arlene S Swern, CL Beach, Eva Hellstrom-Lindberg

Leukemia Research | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2014

Grants

Awarded by Medical Research Council


Funding Acknowledgements

P.F. has received research funding and honoraria from Celgene Corporation; J.F.S has been a consultant and Speaker's Bureau member for, and has received honoraria and travel support from, Celgene Corporation; V.S. has received honoraria from Celgene Corporation; L.S. has been a consultant for, and has received honoraria from, Celgene Corporation; S.D.G. has been a consultant for, and has received research funding from, Celgene Corporation; A.L. has been a consultant for Celgene Corporation; G.S. has received research funding and honoraria from Celgene Corporation; GJ.M has been a consultant and member of the Speaker's Bureau for, and has received research funding from, Celgene Corporation; E.E. has nothing to disclose; A.S.S. and C.L.B are employed by and have equity ownership in Celgene Corporation; E.H.-L. has been a consultant for, and has received research funding from, Celgene Corporation. Sheila Truten, BS, MC2, Wynnewood, PA provided editorial and writing assistance, which was supported by Celgene Corporation. Celgene Corporation funded the AZA-001 study.